The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Molinelli, Chiara; Bruzzone, Marco; Blondeaux, Eva; Ruelle, Tommaso; Lanzavecchia, Chiara; De Laurentiis, Michelino; Russo, Stefania; Riccardi, Ferdinando; Sini, Valentina; Cognetti, Francesco; Arpino, Grazia; Fabi, Alessandra; Pugliese, Palma; Collovà, Elena; Fontana, Andrea; Puglisi, Fabio; Bighin, Claudia; Lambertini, Matteo; Del Mastro, Lucia

doi:10.1016/j.ejca.2024.115113

European Journal of Cancer

2024

DOI: 10.1016/j.ejca.2024.115113

|View full text |Cite

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Chiara Molinelli,

Marco Bruzzone,

Eva Blondeaux

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Identification and management of medical comorbidities in patients with HR+/HER2– metastatic breast cancer treated with CDK4/6 inhibitors: literature review and recommendations from experts in Spain opinion

Hinojo,

Cantos,

Antolín

et al. 2024

Clinical Breast Cancer

View full text Add to dashboard Cite

Identification and management of medical comorbidities in patients with HR+/HER2– metastatic breast cancer treated with CDK4/6 inhibitors: literature review and recommendations from experts in Spain opinion

Hinojo,

Cantos,

Antolín

et al. 2024

Clinical Breast Cancer

View full text Add to dashboard Cite

Fulvestrant Monotherapy After CDK4/6 Inhibitors in Metastatic Breast Cancer Patients: A Real-Life Experience

Agostini,

Mandrioli,

Zamagni

2024

Cancers

View full text Add to dashboard Cite

Background: The treatment of hormone receptor positive (HR+), HER-2 negative metastatic breast cancer (MBC) has radically changed over the last few years. CDK4/6 inhibitors combined with endocrine therapy have become the standard of care as a front-line therapeutic approach, conferring a significant improvement in progression-free survival and overall survival compared to traditional endocrine therapy (ET) alone. However, the wide administration of these drugs in clinical practice paved the way for the emergence of new intrinsic and acquired mechanisms of resistance that seem to compromise second-line treatment effectiveness. In this context, fulvestrant monotherapy appears disqualified. Materials and Methods: we evaluated a population of 30 women currently treated in our oncology unit with HR+/HER2- metastatic breast cancer, receiving fulvestrant 500 mg every 28 days after progression to first-line therapy with CDK 4/6 inhibitors combined with aromatase inhibitors. Results: Of 30 patients observed, 23 progressed to fulvestrant with a median PFS of 3.7 months (range 1–9.7 months). Conclusions: our real-life experience suggests that second-line fulvestrant monotherapy confers very poor disease control and is quite an inadequate therapeutic option. CDK4/6i administration beyond progression could possibly be considered as more valid option, in the absence of targetable mutations or newer, more effective drugs.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Cited by 2 publications

References 30 publications

Identification and management of medical comorbidities in patients with HR+/HER2– metastatic breast cancer treated with CDK4/6 inhibitors: literature review and recommendations from experts in Spain opinion

Identification and management of medical comorbidities in patients with HR+/HER2– metastatic breast cancer treated with CDK4/6 inhibitors: literature review and recommendations from experts in Spain opinion

Fulvestrant Monotherapy After CDK4/6 Inhibitors in Metastatic Breast Cancer Patients: A Real-Life Experience

Contact Info

Product

Resources

About